After finishing Herceptin (trastuzumab), you enter a structured follow-up period that typically lasts at least two years. The standard adjuvant course runs 52 weeks, and once that final infusion is done, your oncology team shifts focus to cardiac monitoring, recurrence surveillance, and managing any lingering side effects. Most people feel a mix of relief and anxiety at this stage, which is completely normal.
Cardiac Monitoring Continues for at Least Two Years
Herceptin can affect heart function, which is why your doctors monitored your heart’s pumping ability (called left ventricular ejection fraction, or LVEF) every three months during treatment. That monitoring doesn’t stop when treatment ends. The FDA prescribing information calls for heart function assessments every six months for at least two years after completing adjuvant Herceptin therapy.
These checks are typically done with an echocardiogram or a similar imaging scan. Your care team is looking for any decline in how efficiently your heart pumps blood. The good news: clinical trial data shows that cardiac events after finishing Herceptin are uncommon during long-term follow-up. If your heart function stayed stable throughout treatment, it’s likely to remain that way. Still, let your doctor know if you develop swollen feet or ankles, shortness of breath, or chest pain at any point after treatment ends.
Side Effects That May Linger
Many Herceptin side effects fade after treatment stops, but some take longer to resolve than others. Fatigue is one of the most common complaints in the months following your last infusion. It can take weeks or even several months before your energy levels feel close to normal. Sleep disruption often goes hand in hand with fatigue, creating a frustrating cycle.
Joint and muscle pain is another side effect that can persist for a while, particularly if you also received chemotherapy alongside Herceptin. A heat pad or hot water bottle can help with mild discomfort. Over-the-counter pain relief is reasonable for moderate symptoms, but pain that doesn’t improve over time is worth bringing up with your oncologist. For most people, these aches gradually improve as the drug clears your system and your body recovers from the cumulative effects of treatment.
Watching for Recurrence
Once active treatment is over, regular check-ups with your oncology team become your primary safety net for catching any recurrence early. The specific schedule varies, but visits are generally more frequent in the first two to three years, when recurrence risk is highest, and then gradually space out.
Between appointments, knowing what to watch for matters. Local or regional recurrence can show up as a new lump or area of firmness in the breast or chest wall, changes in breast size or shape, skin dimpling or redness, a nipple that turns inward or flattens, or swollen lymph nodes under your arm, near your collarbone, or in your neck. Thickening or pulling around a surgical scar is also worth reporting.
Distant recurrence, where cancer has spread to other parts of the body, produces different symptoms. These include persistent or worsening bone, back, or hip pain; headaches with dizziness or balance problems; shortness of breath or a cough that won’t go away; unexplained weight loss or appetite loss; numbness or weakness anywhere in the body; and yellowing of the skin or eyes. None of these symptoms automatically means cancer has returned, but any of them warrant a call to your oncologist rather than a wait-and-see approach.
Extended Therapy After Herceptin
For some patients, finishing Herceptin doesn’t mean finishing targeted therapy entirely. An oral medication called neratinib (brand name Nerlynx) is approved for extended adjuvant treatment in adults with early-stage HER2-positive breast cancer who have already completed trastuzumab-based therapy. It’s typically started within two years of finishing Herceptin and taken daily for one year.
Not everyone is a candidate for extended therapy. Your oncologist will weigh factors like your original tumor stage, hormone receptor status, and how you tolerated previous treatment. In the clinical trial that led to its approval, over 2,800 women with early-stage HER2-positive breast cancer were enrolled, and the drug showed a meaningful reduction in recurrence risk for certain subgroups. If your oncologist recommends it, expect a conversation about the benefits versus the side effects, which can include diarrhea that often requires proactive management.
Rebuilding Energy and Strength
Physical activity after finishing Herceptin is both safe and beneficial for most people. Exercise improves energy levels, helps manage treatment-related fatigue, and can lower the risk of cancer returning. You don’t need to train for a marathon. Walking, swimming, yoga, or light resistance training all count, and starting slowly is perfectly fine. The key is consistency rather than intensity, especially in the early months of recovery.
Nutrition plays a complementary role. After treatment ends, eating a balanced diet helps your body regain strength, supports immune function, and can improve how you feel day to day. The American Cancer Society recommends that cancer survivors focus on whole grains, fruits, vegetables, and lean protein while limiting alcohol. There’s no single “anti-cancer diet,” but the evidence consistently points toward these basics as a foundation for long-term health.
The Emotional Transition
One of the least discussed aspects of finishing Herceptin is the psychological shift. During treatment, you had regular appointments, infusions, and a clear plan. Afterward, the sudden drop in medical contact can feel unsettling. Many people describe a paradox: they looked forward to finishing treatment, then felt more anxious once it was over. Every new ache or pain can trigger worry about recurrence.
This is not a personal failing. It’s an extremely common experience among cancer survivors. Support groups, counseling, and open conversations with your care team can all help during this transition. Your oncology team expects these concerns and can help you distinguish between normal post-treatment symptoms and signals that need investigation.